Kaya Ltd

- There was a mention of further loans given by promoters, with an additional INR37 crores, bringing total promoter loans to around INR150 crores (Page 9). - However, this loan is currently an approval to draw down as needed and has not been fully utilized yet. - The board is evaluating options for repayment, including possible right issues or conversion strategies, but no definite plan has been provided yet (Page 9). - Management has not given any specific guidance or confirmation regarding new fundraising through debt or equity in the near term. - They mentioned they would come out soon with some outcome on repayment or fundraising options (Page 9). - No direct mention of any immediate future fundraising through new debt or equity beyond this promoter loan approval.

- Kaya Limited spent approximately INR 14 crores on capex in Q1 FY '24, mainly towards machines and brand refresh. (Page 4) - Future capex may increase if there is further capitalization of machines or equipment, but no specific guidance is provided. (Page 6) - The company is evaluating opportunities to invest further in the body contouring vertical, subject to business performance improvements and pilot success. (Page 4) - No exact figures or timelines for future capex or strategic investments were disclosed, and management refrained from giving forward-looking guidance on this topic. (Page 10)

- The company does not provide explicit forward-looking sales or growth guidance due to regulatory and market considerations. - Management is focusing on increasing customer counts through initiatives like marketing automation, improved customer experience, and launching new service verticals such as body contouring. - The body segment, especially body sculpting, has shown a 5x growth in collections, indicating strong future potential. - Nutraceuticals are contributing significantly and are expected to grow. - Expansion into Tier 2 cities and new geographies continues, which may support growth. - Q1 FY '24 showed 14% consolidated revenue growth over last year, signaling positive momentum. - While exact revenue targets are not announced, management indicates that ongoing strategies and initiatives are expected to support sustained growth.

- The company has not provided explicit guidance on future earnings, operating profits, or EPS growth due to regulatory and market sensitivity. - Q1 FY '24 showed improvement with consolidated EBITDA at INR12.9 crores vs. loss of INR5.6 crores in Q1 FY '23. - Loss after tax improved significantly from INR23.5 crores (Q1 FY '23) to INR9.3 crores (Q1 FY '24). - Management highlighted initiatives to increase customer count, including new verticals and technology-driven customer acquisition and retention strategies. - Growth in customer volume is a key focus but no quantitative guidance on customer count or revenue growth was given. - Margin sustainability is expected, with fixed and variable costs managed closely; margins on high-margin businesses are north of 70%. - Expansion is cautious with 4 new clinics recently opened, focusing on breakeven before further rollout. - Overall, the company emphasizes qualitative improvements and incremental growth but refrains from explicit forward-looking earnings guidance.

The transcript provided from the Kaya Limited Q1 FY '24 Earnings Conference Call does not mention any details regarding current, expected orderbook, or pending orders. There is no discussion or disclosure related to orderbook status or backlog in the available pages (1 to 10). The focus of the call is primarily on financial performance, store metrics, customer acquisition, margins, regional performance, and strategies for growth and expansion. **Summary:** - No information disclosed about current or expected orderbook or pending orders. - Discussions centered on revenue, profitability, clinic performance, and growth initiatives. - No guidance or commentary on order backlog provided during the call.